Inventiva's Total Assets for the quarter that ended in Dec. 2025 was €249.51 Mil.
During the past 12 months, Inventiva's average Total Assets Growth Rate was -16.80% per year.
During the past 3 years, the average Total Assets Growth Rate was -12.90% per year.
During the past 5 years, the average Total Assets Growth Rate was -4.90% per year.
During the past 10 years, the average Total Assets Growth Rate was -0.10% per year.
During the past 13 years, Inventiva's highest 3-Year average Total Assets Growth Rate was 19.10%. The lowest was -35.10%. And the median was -4.95%.
Total Assets is connected with ROA %. Inventiva's annualizedROA % for the quarter that ended in Dec. 2025 was -166.41%. Total Assets is also linked to Revenue through Asset Turnover. Inventiva's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Inventiva's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Inventiva Total Assets Related Terms
Inventiva Total Assets Historical Data
* Premium members only.
The historical data trend for Inventiva's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Inventiva's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventiva (CHIX:IVAP) has a Total Assets of €249.51 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Inventiva and its competitors.
Is Inventiva's Total Assets too high?
Inventiva's current Total Assets is €249.51 Mil. Overall, Inventiva has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Total Assets compare to VRTX and REGN?
Inventiva's Total Assets of €249.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Inventiva and its competitors. Inventiva's current Total Assets is €249.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (CHIX:IVAP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.06 — trading 1175% above its estimated fair value. The current Total Assets is €249.51 Mil. Inventiva's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Inventiva (CHIX:IVAP), the current Total Assets is €249.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inventiva (CHIX:IVAP) Overvalued in 2026?
Based on GuruFocus' analysis, Inventiva stock appears to be overvalued.
The current stock price of €3.06 is trading 1175% above its estimated GF Value™ of €0.24.
GuruFocus considers Inventiva to be Significantly Overvalued.
Key valuation signals for CHIX:IVAP:
Total Assets: €249.51 Mil
GF Value™: €0.24 vs. price of €3.06 (1175% above fair value)
No single metric tells the full story. See the CHIX:IVAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
53GF Score
Get the complete analysis for CHIX:IVAP
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:IVAP has been successfully added to your 
